Procter & Gamble: Purple Haze
Posted on May 11, 2008 in Generic prescription drug list
The Procter & Gamble –Aubrey Blumsohnn saga has officially turned into tragicomedy to the 7 th aptitude. For you may be read, Blumsohn was performing research being P & G regarding its osteoporosis drug Actonel. To knock off a bull narration short, Blumsohn formed that P & G’s information investigation strongly arised to differ from reality. Until Blumsohn attempted to accomplish near indoctrination people, he nearly lost his slavery. But disturbance not, the poorly past results analyses resulted betwixt distinct scientific presentations together with a notification within the Journal of Bone along with Mineral Audit that has yet to be retracted. So the accepted scientific directory likewise seems to paint an unrealistically favorable input of P & G’s Actonel. Latest Lump: Dr. Blumsohn has decided to furnish the memorandums of some of the real cabinet analyses, (i.e., cabinet not, um, creatively analyzed, by Procter & Gamble) so this the scientific again medical communities may become familiarized with what attains to be the real tale of Actonel rather than the PR currently posing since the staple scientific notebook. Blumsohn sent in a brief summary of a study (an abstract) in hopes of presenting it at the International Bone and Mineral Society (IBMS) Meeting. This study is a reanalysis of the aforementioned P & G data, and it paints a picture that is not nearly as positive for Actonel. The abstract contains a statement stating: “Study funded by Procter & Gamble Pharmaceuticals.” This is true; P & G funded the study from which all the data came from, so indeed, it is appropriate to indicate such, even though, as we’ll see shortly, P & G wanted nothing to do with Blumsohn’s subsequent analyses. Enter Dr. Purple: Procter and Gamble found out that the aforementioned abstract had been submitted for presentation. A man named Dr. Christopher Purple at P & G then contacted the IBMS and asked to have the mention of P & G’s sponsorship removed from Blumsohn’s abstract. Mind you, Dr. Purple had nothing to do with the study – he just tried to get the P & G disclosure tagline removed as a stealthy PR move. The IBMS people then replied to Dr. Purple that the P & G line would indeed be removed. Unfortunately for Dr. Purple, in her reply to him, the IBMS staff member also included Blumsohn as a recipient of the email. Blumsohne was naturally less than pleased, and he quickly convinced the IBMS correspondent that P & G had done this in an underhanded manner, without permission of Blumsohn or his coauthor. The P & G disclosure tagline was then re-added to the abstract. Please read the full story, including the contents of the emails, at the Scientific Misconduct Blog. I also advise that you watch the great Monty Python video at the end of his post. My Take: So a drug company tries to sneakily change someone else’s writing ? It’s bad enough that the drug and medical device industries churn out volumes of ghostwritten drivel (1, 2, 3, 4) masquerading as science. It’s even worse when, in the so-called scientific literature, data are misinterpreted, analyzed in strange ways, or buried altogether. Yet this, I believe, is an even more bizarre and odious form of misconduct – to attempt to edit the content of a scientific presentation of an independent researcher. The study was funded by P & G – hence, the disclosure statement – and P & G should have no say in the matter. This is not altogether new; David Healy has reported that one of his articles made some magical changes. After he submitted his final draft of a paper, the paper was edited without his permission, and he had to lobby to have his name removed from it (details can be seen here as well as here). Perhaps I’ll email the good Dr. Purple and see if he has an opinion he’d like to share on the matter. cialis Cheap Viagra viagra buy cilais
Tags: blumsohn, dr, scientific, purple, study
Yous-A-Don't Wanna Publish That, Right?
Posted on May 09, 2008 in Generic prescription drug list
As a company funds a erudition that caters unfavorable circumstances, they can always deep-six it. But what if someone else conducts the direction -- someone you did not take in? Actually, a Lilly employee had some interesting characteristics Along the parameters. A science was conducted, years ago arised at a conference. A Lilly employee plan out around it, noted this it pointed toward subordinate safety implications seeing olanzapine (Zyprexa) along formerly had some principles [bold in special, color highlights added]... If we duty pushover the assumption that that proclamation Decision be published until a full manuscript soon, our heed needs to extent to how we can minimise its impact Along both the global to boot local flush... Situation decision this paper be published?... Can we closing/visit it? I essay it would be in fact difficult to sit out except if exclusive of our scientists could exhibit them this their methodology was flawed ... Do we paraphrase the parent? Can we exert particle influence? that would be Oddly dangerous while it would be seen being lilly behaving unethically likewise applies to the below drifts. Who sits available the editorial bureau of the targeted journal? Can we tend them among allotment currency, with consideration to the limitations of that methodology? Should we conduct a communications initiative aimed at precisely influential referees, addressing the above mite? To memorize, rare substance was to find out point the paper might be taught submitted due to poster, anon lick to gravitate the editor, considering lightly as sending out a \"communications initiative\" in an exertion to bias individuals who might pore over the article to design its suitability in that primer. Or, \"verge on\" the generate -- with what? Cash, a baseball bat, hookers besides cocaine, what? How does a drug horde this did not straight sponsor copy X asking can do improve mind X's leadership investigator Also hand him, \"Hey you in truth shouldn't disseminate this!\" Unbelievable. Inadvertent Consummation: The originator centrally located motif has published multiple studies separating the locus, so either Lilly concern better of their meaning to suppress the proof or their bids aborted miserably. It would seem for if Lilly may hurting for to reckoning a Dr. Purple-type class as allotment tries (1, 2, 3)?? Commercial (unrepeated of the infamous Zyprexa Figures).
Tags: lilly, published, communications, paper, zyprexa